Aldosterone suppresses insulin signaling via the downregulation of insulin receptor substrate-1 in vascular smooth muscle cells

Hypertension

Volumn 50, Issue 4, 2007, Pages 750-755

  Hitomi, Hirofumi ^a,b   Kiyomoto, Hideyasu ^a   Nishiyama, Akira ^a   Hara, Taiga ^a   Moriwaki, Kumiko ^a   Kaifu, Kumiko ^a   Ihara, Genei ^a   Fujita, Yoshiko ^a   Ugawa, Toyomu ^a   Kohno, Masakazu ^a  

^a KAGAWA UNIVERSITY   (Japan)

^b KAGAWA UNIVERSITY   (Japan)

Author keywords

Aldosterone; Eplerenone; Insulin receptor substrate 1; Insulin resistance; Metabolic syndrome; Oxidative stress; Type 2 diabetes mellitus

Indexed keywords

4 AMINO 7 TERT BUTYL 5 (4 METHYLPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; ACETYLCYSTEINE; ALDOSTERONE; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; DEOXYGLUCOSE; EBSELEN; EPLERENONE; GLUCOSE; INSULIN; INSULIN RECEPTOR ANTIBODY; INSULIN RECEPTOR SUBSTRATE 1; PROTEASOME; PROTEASOME INHIBITOR; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; REACTIVE OXYGEN METABOLITE;

ANIMAL CELL; CONFERENCE PAPER; DOWN REGULATION; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; INSULIN RESISTANCE; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE; WESTERN BLOTTING;

ALDOSTERONE; ANGIOTENSIN II; ANIMALS; CELLS, CULTURED; DOWN-REGULATION; INSULIN; INSULIN RESISTANCE; MUSCLE, SMOOTH, VASCULAR; ONCOGENE PROTEIN V-AKT; PHOSPHOPROTEINS; PHOSPHORYLATION; PROTEASOME ENDOPEPTIDASE COMPLEX; RATS; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES;

EID: 34548850880     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.107.093955     Document Type: Conference Paper

References (35)

1. Savage DB, Petersen KF, Shulman GI. Mechanisms of insulin resistance in humans and possible links with inflammation. Hypertension. 2005;45:828-833.
2. Pravenec M, Kurtz TW. Molecular genetics of experimental hypertension and the metabolic syndrome: from gene pathways to new therapies. Hypertension. 2007;49:941-952.
3. Sowers JR, Standley PR, Ram JL, Jacober S, Simpson L, Rose K. Hyperinsulinemia, insulin resistance, and hyperglycemia: contributing factors in the pathogenesis of hypertension and atherosclerosis. Am J Hypertens. 1993;6:260S-270S.
4. Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension. 2001;37:1053-1059.
5. Jay D, Hitomi H, Griendling KK. Oxidative stress and diabetic cardiovascular complications. Free Radic Biol Med. 2006;40:183-192.
6. White MF. IRS proteins and the common path to diabetes. Am J Physiol Endocrinol Metab. 2002;283:E413-E422.
7. Taniyama Y, Hitomi H, Shah A, Alexander RW, Griendling KK. Mechanisms of reactive oxygen species-dependent downregulation of insulin receptor substrate-1 by angiotensin II. Arterioscler Thromb Vasc Biol. 2005;25:1142-1147.
8. Callera GE, Touyz RM, Tostes RC, Yogi A, He Y, Malkinson S, Schiffrin EL. Aldosterone activates vascular p38MAP kinase and NADPH oxidase via c-Src. Hypertension. 2005;45:773-779.
9. Kobayashi N, Yoshida K, Nakano S, Ohno T, Honda T, Tsubokou Y, Matsuoka H. Cardioprotective mechanisms of eplerenone on cardiac performance and remodeling in failing rat hearts. Hypertension. 2006;47:671-679.
10. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309-1321.
11. Conn JW. Hypertension, the potassium ion and impaired carbohydrate tolerance. N Engl J Med. 1965;273:1135-1143.
12. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 2003;26(suppl 1):S5-S20.
13. Schirpenbach C, Reincke M. Primary aldosteronism: current knowledge and controversies in Conn's syndrome. Nat Clin Pract Endocrinol Metab. 2007;3:220-227.
14. Shimamoto K, Shiiki M, Ise T, Miyazaki Y, Higashiura K, Fukuoka M, Hirata A, Masuda A, Nakagawa M, Iimura O. Does insulin resistance participate in an impaired glucose tolerance in primary aldosteronism? J Hum Hypertens. 1994;8:755-759.
15. Giacchetti G, Ronconi V, Turchi F, Agostinelli L, Mantero F, Rilli S, Boscaro M. Aldosterone as a key mediator of the cardiometabolic syndrome in primary aldosteronism: an observational study. J Hypertens. 2007;25:177-186.
16. Hitomi H, Fukui T, Moriwaki K, Matsubara K, Sun GP, Rahman M, Nishiyama A, Kiyomoto H, Kimura S, Ohmori K, Abe Y, Kohno M. Synergistic effect of mechanical stretch and angiotensin II on superoxide production via NADPH oxidase in vascular smooth muscle cells. J Hypertens. 2006;24:1089-1095.
17. Ishizawa K, Izawa Y, Ito H, Miki C, Miyata K, Fujita Y, Kanematsu Y, Tsuchiya K, Tamaki T, Nishiyama A, Yoshizumi M. Aldosterone stimulates vascular smooth muscle cell proliferation via big mitogen-activated protein kinase 1 activation. Hypertension. 2005;46:1046-1052.
18. Mehta PK, Griendling KK. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol. 2007;292:C82-C97.
19. Clempus RE, Griendling KK. Reactive oxygen species signaling in vascular smooth muscle cells. Cardiovasc Res. 2006;71:216-225.
20. Weber DS, Taniyama Y, Rocic P, Seshiah PN, Dechert MA, Gerthoffer WT, Griendling KK. Phosphoinositide-dependent kinase 1 and p21-activated protein kinase mediate reactive oxygen species-dependent regulation of platelet-derived growth factor-induced smooth muscle cell migration. Circ Res. 2004;94:1219-1226.
21. Mick VE, Itani OA, Loftus RW, Husted RF, Schmidt TJ, Thomas CP. The alpha-subunit of the epithelial sodium channel is an aldosterone-induced transcript in mammalian collecting ducts, and this transcriptional response is mediated via distinct cis-elements in the 5′-flanking region of the gene. Mol Endocrinol. 2001;15:575-588.
22. Yamashita R, Kikuchi T, Mori Y, Aoki K, Kaburagi Y, Yasuda K, Sekihara H. Aldosterone stimulates gene expression of hepatic gluconeogenic enzymes through the glucocorticoid receptor in a manner independent of the protein kinase B cascade. Endocr J. 2004;51:243-251.
23. Qi D, Rodrigues B. Glucocorticoids produce whole body insulin resistance with changes in cardiac metabolism. Am J Physiol Endocrinol Metab. 2007;292:E654-E667.
24. Witchel SF, DeFranco DB. Mechanisms of disease: regulation of glucocorticoid and receptor levels-impact on the metabolic syndrome. Nat Clin Pract Endocrinol Metab. 2006;2:621-631.
25. Wei Y, Sowers JR, Nistala R, Gong H, Uptergrove GM, Clark SE, Morris EM, Szary N, Manrique C, Stump CS. Angiotensin II-induced NADPH oxidase activation impairs insulin signaling in skeletal muscle cells. J Biol Chem. 2006;281:35137-35146.
26. Izawa Y, Yoshizumi M, Fujita Y, Ali N, Kanematsu Y, Ishizawa K, Tsuchiya K, Obata T, Ebina Y, Tomita S, Tamaki T. ERK1/2 activation by angiotensin II inhibits insulin-induced glucose uptake in vascular smooth muscle cells. Exp Cell Res. 2005;308:291-299.
27. Haluzik M, Sindelka G, Widimsky J Jr, Prazny M, Zelinka T, Skrha J. Serum leptin levels in patients with primary hyperaldosteronism before and after treatment: relationships to insulin sensitivity. J Hum Hypertens. 2002;16:41-45.
28. Skrha J, Haas T, Sindelka G, Prazny M, Widimsky J, Cibula D, Svacina S. Comparison of the insulin action parameters from hyperinsulinemic clamps with homeostasis model assessment and QUICKI indexes in subjects with different endocrine disorders. J Clin Endocrinol Metab. 2004;89:135-141.
29. Giacchetti G, Sechi LA, Rilli S, Carey RM. The renin-angiotensin- aldosterone system, glucose metabolism and diabetes. Trends Endocrinol Metab. 2005;16:120-126.
30. Corry DB, Tuck ML. The effect of aldosterone on glucose metabolism. Curr Hypertens Rep. 2003;5:106-109.
31. Kraus D, Jager J, Meier B, Fasshauer M, Klein J. Aldosterone inhibits uncoupling protein-1, induces insulin resistance, and stimulates proinflammatory adipokines in adipocytes. Horm Metab Res. 2005;37:455-459.
32. Catena C, Lapenna R, Baroselli S, Nadalini E, Colussi G, Novello M, Favret G, Melis A, Cavarape A, Sechi LA. Insulin sensitivity in patients with primary aldosteronism: a follow-up study. J Clin Endocrinol Metab. 2006;91:3457-3463.
33. Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal. Joint statement from the Am Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2005;48:1684-1699.
34. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA. 2002;287:2570-2581.
35. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-869.